Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

This study examined the safety and tolerability of erlotinib and the heat shock protein 90 inhibitor onalespib in EGFR-mutant non–small cell lung cancer (NSCLC). The phase II component examined preliminary efficacy in epidermal growth factor receptor exon 20 insertion (EGFRex20ins) NSCLC. Overlappin...

Descripción completa

Detalles Bibliográficos
Autores principales: Riess, Jonathan W, Reckamp, Karen L, Frankel, Paul, Longmate, Jeffrey, Kelly, Karen A, Gandara, David R, Weipert, Caroline M, Raymond, Victoria M, Keer, Harold N, Mack, Philip C, Newman, Edward M, Lara, Primo N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239707/
https://www.ncbi.nlm.nih.gov/pubmed/34140248
http://dx.doi.org/10.1016/j.cllc.2021.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239707/
https://www.ncbi.nlm.nih.gov/pubmed/34140248
http://dx.doi.org/10.1016/j.cllc.2021.05.001

Ejemplares similares